Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years

Yukai Zhang, Lei Wang, Yanxia Wang, Wei Zhang, Ningning Jia, Zhiqiang Xie, Lili Huang, Wangyang You, Weifeng Lu, Erwei Li, Feilong Gao, Yuansheng Hu, Fanhong Meng, Shengli Xia, Yukai Zhang, Lei Wang, Yanxia Wang, Wei Zhang, Ningning Jia, Zhiqiang Xie, Lili Huang, Wangyang You, Weifeng Lu, Erwei Li, Feilong Gao, Yuansheng Hu, Fanhong Meng, Shengli Xia

Abstract

Aim: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and the immune persistence of a primary dose in 2- to 6-year-old children.

Methods: A phase IV, open-label study was conducted in China. Children previously vaccinated with a single dose of VarV at 1~3 years old received one dose of homologous VarV in the first year, the second year, or the third year after the primary immunization as booster immunization. Immune persistence was evaluated in an immune persistence analysis set, while immunogenicity was evaluated in a per-protocol analysis set, and safety was evaluated in a safety analysis set. The primary endpoint was the seropositive rate and the seroconversion rate of VarV antibody. The trial was registered at ClinicalTrials.gov (NCT02981836).

Results: From July 2018 to August 2020, a total of 849 vaccinated children received the booster vaccination of VarV, one booster dose for each child (301 vaccinated in the first year after primary immunization (Group 1), 276 vaccinated in the second year after primary immunization (Group 2), 272 vaccinated in the third year after primary immunization (Group 3)). The seropositive rates were 99.34%, 97.83%, and 98.16% in Groups 1-3, with GMTs of 1:22.56, 1:18.49, and 1:18.45, respectively. Thirty days after the vaccine booster dose, the seropositive rates of the three groups were all 100% and the seroconversion rates were 52.54%, 67.46%, and 66.67%, with GMTs of 1:68.49, 1:76.32 and 1:78.34, respectively. The seroconversion rates in Groups 2 and 3 were both higher than that in Group 1 (p = 0.0005 and p = 0.0008). The overall incidence of adverse reactions was 7.77%, with 7.64%, 8.33%, and 7.35% in Groups 1, 2, and 3, respectively. The main symptom among adverse reactions was fever, the incidence of which ranged from 5.07% to 6.64% in each group, and no vaccine-related serious adverse events occurred.

Conclusions: VarV had good immune persistence in 1~3 years after primary immunization. A vaccine booster dose for children aged 1~3 years after primary immunization recalled specific immune response to varicella-zoster virus, with no safety concerns increased.

Keywords: booster; immune persistence; immunogenicity; live attenuated varicella vaccine; safety.

Conflict of interest statement

All authors declare that there is no conflict of interests regarding the publication of this paper.

References

    1. Ong C.Y., Low S.G., Vasanwala F.F., Baikunje S., Low L.L. Varicella infections in patients with end stage renal disease: A systematic review. BMC Nephrol. 2018;19:185. doi: 10.1186/s12882-018-0976-4.
    1. Gershon A.A., Breuer J., Cohen J.I., Cohrs R.J., Gershon M.D., Gilden D., Grose C., Hambleton S., Kennedy P.G., Oxman M.N., et al. Varicella zoster virus infection. Nat. Rev. Dis. Primers. 2015;1:15016. doi: 10.1038/nrdp.2015.16.
    1. Ayoade F., Kumar S. StatPearls. StatPearls Publishing LLC.; Treasure Island, FL, USA: 2021. Varicella zoster.
    1. Kennedy P.G. Varicella-zoster virus latency in human ganglia. Rev. Med. Virol. 2002;12:327–334. doi: 10.1002/rmv.362.
    1. Ong A., Goh K.T., editors. A Guide on Infectious Diseases of Public Health Importance in Singapore. 7th ed. Communicable Diseases Division, Ministry of Health; Singapore: Communicable Disease Centre, Tan Tock Seng Hospital; Singapore: 2011.
    1. Gershon A.A. Live attenuated varicella vaccine. J. Infect. Dis. 1985;152:859–862. doi: 10.1093/infdis/152.5.859.
    1. Lopez A.S., Guris D., Zimmerman L., Gladden L., Moore T., Haselow D.T., Loparev V.N., Schmid D.S., Jumaan A.O., Snow S.L. One dose of varicella vaccine does not prevent school outbreaks: Is it time for a second dose? Pediatrics. 2006;117:e1070–e1077. doi: 10.1542/peds.2005-2085.
    1. Zhang M., Gui G.P., Guo F., Fan X.F., Zha R.S. A Centralized Outbreak of Varicella among Children Attending Preschool in Suzhou, China. Biomed. Res. Int. 2020;2020:6183936. doi: 10.1155/2020/6183936.
    1. Wutzler P., Bonanni P., Burgess M., Gershon A., Sáfadi M.A., Casabona G. Varicella vaccination—The global experience. Expert Rev. Vaccines. 2017;16:833–843. doi: 10.1080/14760584.2017.1343669.
    1. Yin M., Xu X., Liang Y., Ni J. Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination: A meta-analysis. Expert Rev. Vaccines. 2018;17:351–362. doi: 10.1080/14760584.2018.1433999.
    1. Bonanni P., Gershon A., Gershon M., Kulcsár A., Papaevangelou V., Rentier B., Sadzot-Delvaux C., Usonis V., Vesikari T., Weil-Olivier C., et al. Primary versus secondary failure after varicella vaccination: Implications for interval between 2 doses. Pediatr Infect. Dis. J. 2013;32:e305–e313. doi: 10.1097/INF.0b013e31828b7def.
    1. Marin M., Güris D., Chaves S.S., Schmid S., Seward J.F. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm. Rep. 2007;56:1–40.
    1. Marin M., Marti M., Kambhampati A., Jeram S.M., Seward J.F. Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics. 2016;137:e20153741. doi: 10.1542/peds.2015-3741.
    1. Klopfer S.O., Stek J.E., Petrecz M., Reisinger K.S., Black S.B., Goveia M.G., Nicholson O., Gardner J.L., Grosso A.D., Brown M.L., et al. Analysis of safety data in children after receiving two doses of ProQuad® (MMRV) Vaccine. 2014;32:7154–7160. doi: 10.1016/j.vaccine.2014.08.067.
    1. Liu Y., Gao S., Zhao J., Wang P., Xu J.F., Li L., Xu X.F., Li Z.C., Ha X.J., Li K.J. Immune Persistence of Freeze-dried Live Attenuated Varicella Vaccine. Chin. J. Biol. 2006;19:420–422. doi: 10.3969/j.issn.1004-5503.2006.04.034.
    1. Liu S.-k., Wang F., Zhang H.B., Ge B.X., Huang M.L., Hu D.B. Study on Immunogenicity of Booster Immunization of Chinese Varicella Vaccine. Chin. J. Vaccines Immun. 2015;21:620–622+610. doi: 10.3760/cma.j.issn.1673-4149.2015.06.018.
    1. Mitra M., Chowdhury J., Basu S., Halder P.P., Mukherjee M., Karadkhele A., Puppalwar G., Jain R. Evaluation of immunogenicity, safety and breakthrough following administration of live attenuated varicella vaccine in two doses three months apart regimen in Indian children. Ther. Adv. Vaccines Immunother. 2020;8:2515135520937216. doi: 10.1177/2515135520937216.
    1. Tugwell B.D., Lee L.E., Gillette H., Lorber E.M., Hedberg K., Cieslak P.R. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 2004;113:455–459. doi: 10.1542/peds.113.3.455.
    1. Maglione M.A., Gidengil C., Das L., Raaen L., Smith A., Chari R., Newberry S., Hempel S., Shanman R., Perry T., et al. Safety of Vaccines Used for Routine Immunization in the United States. Evid. Rep. Technol. Assess. 2014:1–740. doi: 10.23970/ahrqepcerta215.
    1. Huang L., Chen Z., Hu Y., Xie Z., Qiu P., Zhu L., Bao M., Quan Y., Zeng J., Wang Y., et al. Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1–3 years old children: A double-blind, randomized phase III trial. Hum. Vaccines Immunother. 2019;15:822–827. doi: 10.1080/21645515.2018.1551701.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅